Blockade of dopamine D2 receptors in the tuberoinfundibular dopamine pathway causes prolactin release and can lead to hyperprolactinemia if antagonists of dopamine D2 receptors are used. The gene discussed is DRD2; the disease is hyperprolactinemia.